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Monolayer permeabilityVarious growth factors and cytokines are implicated in endothelial dysfunction and blood–retinal barrier
(BRB) breakdown in early diabetic retinopathy (DR). However, cellular and molecular mechanisms that may
underlie the pathology of DR are not fully understood yet. We therefore examined the effect of insulin-like
growth factor (IGF)-1 on ECM/adhesion molecule expression, cell cycle regulation and monolayer
permeability in an endothelial cell line (TR-iBRB2). We investigate whether the action of IGF-1 (1) involves
glycogen synthase kinase 3beta (GSK-3β) and cAMP responsive transcription factor (CREB) and (2) alters
ECM/adhesion molecule gene expression. Treatment of TR-iBRB2 cell with IGF-1 (100 ng/ml for 0–24 h)
increases phosphorylation of (i) Akt Thr308, and its substrates including GSK-3β at Ser9, which inactivates its
kinase function, and (ii) CREB at Ser133 (activation). These phosphorylations correlate positively with
enhanced expression of CREB targets such as ECM protein ﬁbronectin and cell cycle progression factor cyclin
D1. However, stable transfection of a mutant GSK3β(S9A) or a dominant negative K-CREB in TR-iBRB2
prevents IGF-1-induced ﬁbronectin and cyclin D1 expression. Furthermore, IGF-1 reduces the level of
intercellular adherence molecule VE-cadherin and increases monolayer permeability in TR-iBRB2 cells when
measured by FITC-dextran leakage. The effect of IGF-1 on VE-cadherin and membrane permeability is absent
in TR-iBRB2 cells expressing the GSK-3β(S9A). Similarly, K-CREB reverses IGF-1 down-regulation of VE-
cadherin and up-regulation of ﬁbronectin. These results indicate that GSK-3β/CREB axis alters ECM/adhesion
molecule expression and cell cycle progression in retinal endothelial cells, and may potentially contribute to
endothelial dysfunction and BRB leakage in DR.and Cell Biology, Wayne State
32, 540 East Canﬁeld Avenue,
1 313 577 3125.
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ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Diabetic retinopathy (DR) is the most common cause of visual
disorders leading to irreversible blindness. Chronic hyperglycemia-
induced oxidative stress, decreased blood ﬂow, hypoxia and growth
factor-mediated altered gene expression are observed in the diabetic
retina. The complications of DR are associatedwith capillary basement
membrane thickening, blood–retinal barrier (BRB) leakage, endothe-
lial cell proliferation and neovascularisation, capillary cell apoptosis,
and retinal detachment [1–3]. Among the various growth factors
implicated in the development of DR, vascular endothelial growth
factor (VEGF), ﬁbroblast growth factor (FGF) 2, and tumor necrosisgrowth factor (TNF)-α are well characterized [1]. Recent studies have
shown that the insulin-like growth factor (IGF)-1 and IGF-1 receptor
system may be also involved in retinal endothelial cell proliferation
and development of proliferative diabetic retinopathy (PDR) [3–5].
Grant and colleagues also demonstrated that knocking down the IGF-
1 receptor by the expression of proliferating endothelial cell speciﬁc
IGF-1 receptor ribosyme inhibits retinal neovascularization in mouse
models of proliferative retinopathy [6]. Furthermore, in pig and rabbit
models of DR, intravitreal injection of IGF-1 results in the breakdown
of blood–retinal barrier, basement membrane thickening and neo-
vascularization similar to PDR [7,8]. Transgenic mice overexpressing
IGF-1 in the retina develop thickened vessel basement membrane and
several similar clinical parameters of diabetic human eyes are also
found [9].
Increased expression of extracellular matrix (ECM) proteins (e.g.,
ﬁbronectin, laminin and collagen) and down-regulation of intercel-
lular adhesion molecules (e.g., VE-cadherin, claudins and occludins)
are observed in the diabetic retina, which lead to altered cell–matrix
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[10–13]. In addition, an increased expression of apical cell adhesion
molecules such as ICAM1 and VCAM1 in diabetes can lead to leukocyte
adhesion and endothelial inﬂammation of the retina [14].
Glycogen synthase kinase 3beta (GSK-3β) is a signal mediator for
the IGF-1 and PI3-K/Akt pathway that are required for cell
proliferation and survival in many cell types including endothelial
cells [15,16]. Insulin and IGF-1 signaling involve activation of PI3K and
the downstream Akt/PKB kinase, which in turn phosphorylates GSK-
3α at Ser21 and GSK-3β at Ser9, and inhibits their kinase activities
[17–19]. Both isoforms of GSK-3 have a similar range of substrate
speciﬁcities and are regulated in response to growth factor stimula-
tion. However, disruption of GSK-3β gene in mice results in
embryonic lethality, indicating that GSK-3α may not completely
substitute for a loss of GSK-3β [15,20]. Transcription factors are the
signal convergent points for molecular signaling by growth factors
and extracellular agents from where they mediate gene expression
and signal diversiﬁcation in target cells and organs. One such signal
convergent site is the cyclic AMP responsive cis-element binding
transcription factor CREB [21–23]. Most ECM genes contain cyclic
AMP responsive element (CRE) sequences in their promoters and
phosphorylation of CREB at Ser133 is considered to increase CREB/
DNA interaction and gene expression [22]. We have previously shown
that GSK-3β is involved in IGF-1-induced CREB phosphorylation and
downstream cyclin D1 and ﬁbronectin expression in renal mesangial
cells [15,24].
In spite of the critical role(s) of GSK-3β and CREB in cell
proliferation, differentiation, survival and regulation of gene expres-
sion, putative involvement in endothelial dysregulation and DR
remains unclear. Therefore, in the present investigation, we hypoth-
esize that IGF-1 signaling in retinal endothelial cells involves the GSK-
3β/CREB axis and regulates ECM/adhesion molecule expression and
monolayer hyperpermeability. Our results show for the ﬁrst time that
GSK-3β and CREB mediate IGF-1-induced aberrant ECM/adhesion
molecule gene expression and cell cycle progression, which may
constitute a potential mechanism for endothelial dysfunction and BRB
breakdown in DR.
2. Materials and methods
2.1. Materials
Insulin-like growth factor-1, and antibodies for cyclin D1, α-actin,
and phosphorylated Akt at Thr308, total Akt antibodies, phosphorylated
Akt substrate motif speciﬁc antibodies targeted at R-X-R-X-X-S*/T*p
and total and phosphorylated CREB at S133 antibodies were purchased
form Cell Signaling Technology (Danvers, MA). Anti-laminin γ1,
ﬁbronectin, tubulin, and phosphorylated and non-phosphorylated
GSK-3β antibodies were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Pan-cadherin and ICAM1 antibodies were obtained
from Abcam (Cambridge, MA). SH-5 (Akt inhibitor) was from Alexis
(San Diego, CA) while GSK-3β inhibitor, SB216763, was obtained from
Calbiochem (San Diego, CA). The enhanced chemiluminescence (ECL)
system was obtained from Amersham (Arlington Heights, IL). DMEM
and F-12 nutrient mixture (Ham's) were obtained from GIBCO (Grand
Island, NY). Chicken anti-ﬁbronectin antibodies were purchased from
Molecular Probes (Invitrogen, Eugene, OR).
2.2. Cell culture
We used a temperature-sensitive rat retinal endothelial cell line
(TR-iBRB2 for transgenic-eye blood–retinal barrier endothelial cell
line 2), which differentiates normally at 37 °C but proliferates at 33 °C.
TR-iBRB2 cells have been employed previously to investigate retinal
endothelial cell permeability, drug transport across the inner BRB, and
gene expression analysis under various conditions [25,26]. TR-iBRB2cells express endothelial markers, such as von Willebrand factor
(vWF), acetylated low density lipoprotein receptors, VEGF receptor 2
(KDF/Flk-1), glucose transporter Glut-1 and maintain other endothe-
lial properties.
TR-iBRB2 cells were cultured in medium containing DMEM (low
glucose, 5.5 mM) and Ham's F-12 (3:1 ratio) supplemented with 7.5%
fetal calf serum (FCS) and 0.5 mg/ml gentamicin at 33 °C in a
humidiﬁed chamber with a 5% CO2–95% air mixture (26). Monolayers
at 70–80% conﬂuence were transferred to 37 °C and serum-deprived
overnight (0.2% serum medium). As described previously in our
manuscripts [15,24], we performed an initial dose-dependent
experiment of IGF-1 ranging from 0, 5, 25, 50, 100 and 150 ng/ml
on TR-iBRB2 cell viability using MTT assay. We observed that 100 ng/
ml IGF-1 gave the optimal effect on TR-iBRB2 survival; therefore, we
chose this concentration of IGF-1 in subsequent experiments (Fig. S1).
For the time course, IGF-1 with 24 h treatment was added ﬁrst, then
on the second day IGF-1 was added at 4 h and 0 (no addition) to
respective cultures before harvesting. Thus, all cells maintain a similar
condition and length of serum-deprivation during the entire exper-
imental procedure [15]. Cells were harvested by scrapping, snap
frozen and stored at −80 °C until used.
2.3. SDS-PAGE and Western blotting
Proteinswere extracted in RIPAbuffer containingprotease inhibitors
and their concentrations were determined using a Coomassie-based
reagent from Pierce with BSA as the standard. Sodium dodecyl sulfate
polyacrylamide gel electrophoresis and Western blot analysis of
proteins were performed as described previously [15].
2.4. Real-time quantitative PCR
Total RNAs were isolated by TRIZOL method and ﬁrst-strand
cDNAs were synthesized in 20 μl volume using 1 μg RNA the Bio-Rad
iScript cDNA synthesis kit [26]. mRNA expression was analyzed by
real-time quantitative PCR using the MJ Bio-Rad Chromo 4 detection
system and SYBR Green PCR Master Mix from Applied Biosystems
(Foster City, CA). Primers were designed using Primer Express v 2.0
(Applied Biosystems) and synthesized by Invitrogen (Carlsbad, CA).
Primers for the real-time Q-PCR are as follows:1. Fibronectin: Forward: 5′-CTGGGGTCACGTACCTCTTCA-3′
Reverse: 5′-AGTCGGTAGCCTGCTATACGG-3′;2. Laminin γ1: Forward: 5′-TGCTGTGATCTCAGACACTTACTTC-3′
Reverse: 5′-TGAAGATGTACTTCACAGTGGTCTC-3′3. Actin: Forward: 5′-GGCTGCCTCGAAATTACAACA-3′
Reverse: 5′-CCAGCAGATTCCATACCAATGAAAG-3′The real-time PCR reaction mixture contained 1× SYBR Green PCR
Master Mix, 400 nM forward and reverse primers, and 2 μl cDNA in a
ﬁnal volume of 25 μl. The PCR cycling was programmed as 95 °C for
15 s, 55 °C for 30 s and 72 °C for 45 s 40 cycles followed by the
construction of a melting curve through increasing the temperature
from 60 to 95 °C at a ramp rate of 2% for 20 min. The real-time PCR
samples were evaluated using a single predominant peak as a quality
control. Ct values were used to calculate the relative expression level
of ECM mRNAs that were normalized to actin [26].
2.5. Determination of cell viability and DNA content
We used three approaches to measure cell viability and DNA
content. (A) MTT assay for cell viability was performed in 24-well
plates and with 0.5 mg/mlMTT in eachwell as previously described in
our laboratory [24,27]. TR-iBRB2 cells (1×104 cells) were grown to
70% conﬂuence and serum-starved overnight. IGF-1 100 ng/ml was
added for 4–24 h andMTTwas added for 3 h. The media was removed
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was diluted with 500 μl of distilled H2O and detected at 570 nm using
a Gemini Microplate reader. (B) Cell Live/Death assay was measured
with a ﬂuorescence reagent from Molecular Probes as previously
described [15,27]. Brieﬂy, to determine live and dead cells simulta-
neously, a ﬂuorescent multiwell plate assay (Molecular Probes) was
performed under conditions similar to the MTT assay using 24-well
plates according to the manufacturer's instructions using calcein AM
and ethidium homodimer-1. Live cells are measured by the conver-
sion of cell membrane permeable non-ﬂuorescent calcein AM dye,
which is converted by intracellular esterases to intensely ﬂuorescent
calcein at 515 nmwhen excited at 495 nm. On the other hand, EthD-1
enters cells with damaged membranes and undergoes a 40-fold
increase in ﬂuorescence upon binding to DNA (emission and excitation
wavelengths at 528/617 nm). (C) DNA contents were determined with
CyQUANT kit based on a ﬂuorescence enhancement of dye binding to
cellular nucleic acids as described recently [24]. After IGF-1 treatment,
cells were washed with cold PBS three times and stored at−80 °C for
1 h. Plates were taken out of the freezer and incubatedwith DNAse-free
RNAse (1.35 Units/ml) for 1 h at room temperature to digest RNA. DNA
content was measured by CyQuant Dye binding at Ex480/Em520 with
the bottom read and scanning device of a Spectra MAX Gemini EM
Fluorescence microplate reader.
2.6. Stable transfection of GSK-3β(S9A) and K-CREB expression vectors
in TR-iBRB2 cells
Constitutively active Ser9 to Ala mutated GSK-3β(S9A) and dominant
negative K-CREB in pcDNA3.1 plasmids were used to transfect TR-iBRB2
cells. A corresponding empty pcDNA3.1 served as control cells. Expression
vector for GSK-3β(S9A) was kindly provided by Dr. Woodgett from the
University of Toronto Health Sciences, Toronto, and K-CREB plasmid was
purchased from Clontech. TR-iBRB2 cells were plated in 6- or 12-well
plates and grown overnight to ~70–80% conﬂuence and serum-starved.
Cells were transfected with 2.0–4.0 μg DNA per well in 100 μl serum-free
DMEM containing 20 μl of Lipofectamine 2000 (Invitrogen) in duplicateFig. 1. IGF-1 activates AKT/GSK-3β/CREB signaling in retinal capillary endothelial cells in cul
extracted in RIPA buffer and 30 μg proteins were subjected toWestern blotting. (A) IGF-1 (10
also increases phosphorylation of several Akt targets at 4 and 24 h including hyperphosphor
using an antibody that recognizes phosphorylated Akt substrates. The blot is a representativ
24 h ~4.5- and 3.3-fold, respectively, when compared with controls at 0 time (*, pb0.05 for
CREB at Ser133 was performed and normalized by total GSK-3β. Representative blots of ph
increases phosphorylation of CREB at Ser133 approximately ~3-fold at 4 and 24 h (*, pb0.05
Western blots and their densitometric ratio of CREBp/CREB was determined.wells. Six hours later, the media were replaced with serum containing
DMEM:F-12 (3:1 ratio)mediumandwere further grown to reach 90–95%
conﬂuence at 33 °C. Stable cell lines were selected under the inﬂuence of
G418 as previously described [15,26]. Cell passages between 4 and 8were
used. The cells were transferred to 37 °C and further experiments were
performed. The effect of GSK-3β(S9A) and K-CREBwasmonitored by CRE
promoter activity using a mammalian expression vector containing the
CRE element with a reporter secretory alkaline phosphatase (CRE-SEAP)
from Clontech. The CRE-SEAP vector was transiently transfected in
pcDNA3.1, GSK-3β(S9A) and K-CREB cells and SEAP activitywas detected
in the media using a ﬂuorescence detection kit according to the
manufacturer's instructions.
2.7. In vitro endothelial monolayer permeability assay
The effects of IGF-1 on endothelial monolayer permeability were
measured using an in vitro Vascular Permeability Assay Kit (Chemicon
International) according to the manufacturer's instructions. Brieﬂy,
24-well tissue culture plates with semi-porus membrane inserts of
1.0 μm symmetrical pores are coated with collagen 1α. TR-iBRB2 cells
were grown in these inserts to form conﬂuent monolayer for 2 days at
33 °C. Afterwards, the cells were transferred to 37 °C in serum-
deprivedmedia (0.2% serum) overnight. Subsequently, IGF-1 (100 ng/
ml) was added to the cells for another 24 h. The extent of monolayer
permeability was determined on day 4 by adding 40 kDa FITC-Dextran
provided in the kit on top of the cells for 30 min. Hundred microliters
of the media from the lower chamber was measured for ﬂuorescent
detection in 96 wells with a SpectraMAX GeminiEM Fluoremeter at
ex485/em530 nm to determine the extent of leakage.
2.8. Statistical analysis
Results are expressed as means +/− SE. Student's t-test or one
way ANOVA followed by Bonferroni post hoc test was used to
compare differences between treatment conditions. A preset P value
of b0.05 was considered statistically signiﬁcant.ture. TR-iBRB2 cell were treated with IGF-1 (100 ng/ml) for 0, 4, 24 h and proteins were
0 ng/ml) induces Akt phosphorylation at Thr308 in TR-iBRB2 cells (upper panel). IGF-1
ylated proteins at 48kDa (* molecular size of GSK-3β) and 32 kDa (arrow, lower panel)
e of 3 different experiments. (B) IGF-1 increases GSK-3β Ser9 phosphorylation at 4 and
both). Densitometric analysis of Western blots for phosphorylated GSK-3β at Ser9 and
osphorylation of GSK-3β at Ser9, total GSK-3β and actin are shown (n=3). (C) IGF-1
versus time 0, n=3). Phosphorylated CREB at Ser133 and total CREB were measured on
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3.1. IGF-1 activates Akt/GSK-3β/CREB pathway and induces cell cycle
progression and ECM protein expression in retinal endothelial cells
To understand the signaling mechanism of IGF-1 in endothelial
gene expression, we examined different downstream signaling
targets of IGF-1 receptor including Akt/GSK-3β/CREB axis as previ-
ously described for renal mesangial cells [15,24]. TR-iBRB2 cells were
treated with IGF-1 (100 ng/ml) for 0, 4, and 24 h and total cellular
extracts were subjected to Western blotting with primary antibodies
targeted against phosphorylated Akt at Thr308, and total Akt. In
addition, a phosphorylated Akt peptide motif (R-X-R-X-X-S*/T*p)
speciﬁc antibody, which recognizes most phosphoproteins that are
targeted by Akt, was also used to determine Akt activation and
substrate phosphorylation. As shown in Fig. 1A, IGF-1 increases Akt
phosphorylation at Thr308 (upper panel), and several Akt targeted
phosphoproteins of different molecular sizes (as indicated by arrows,
lower panel). This result demonstrates that IGF-1 increases Akt
activity and induces phosphorylation of several proteins including a
protein at 48 kDa. The 48-kDa protein is the predicted molecular size
of an Akt target protein, GSK-3β. In agreement, the extent of GSK-
3β(S9) phosphorylation is signiﬁcantly increased by IGF-1 at 4 h andFig. 2. IGF-1 increases ﬁbronectin and cyclin D1 expression in retinal capillary endothelial
cells. (A) Treatment of TR-iBRB2 cells with IGF-1 increases ﬁbronectin levels signiﬁcantly
at 4 and 24 h (~2-fold; pb0.05 versus time 0; n=3). Actin was not changed. Panel below
shows densitometric analysis of ﬁbronectin bands in gels. (B) Similarly, cyclin D1 is also
increasedby IGF-1 at4 and24 h signiﬁcantly (pb0.05;n=3). Panel below shows cyclinD1
densitometric analysis.continues up to 24 h period (pb0.01 versus time 0 for both) (Fig. 1B).
However, total GSK-3β level is not changed by IGF-1 treatment.
Furthermore, downstream transcription factor CREB phosphorylation
at Ser133 is also increased, whereas total CREB content is not altered
(Fig. 1C). We have previously shown that CREB is involved in gene
transcription for cell cycle regulation and ECMs [24,28]; therefore, we
further examined the expression of cell cycle control protein cyclin D1
and sclerotic ﬁbronectin. As shown in Fig. 2, ﬁbronectin (A) and cyclin
D1 (B) expressions are increased by IGF-1 signiﬁcantly at 4 and 24 h
(pb0.05 versus time 0, n=3). These data indicate that IGF-1 signaling
leads to intracellular Akt/GSK-3β/CREB pathway activation and
correlates positively with cell cycle progression and ECM expression.3.2. IGF-1 enhances endothelial cell viability and DNA synthesis
IGF-1 is a survival and proliferation factor for various cell types
including the retina and Akt/GSK-3β plays important roles in these
processes. Therefore, we investigated further if IGF-1 treatment of TR-
iBRB2 enhances cell viability and DNA synthesis. IGF-1 treatment of
TR-iBRB2 increases viability in a time-dependent manner at 24 h
(pb0.05 versus time 0) as measured by MTT and Live/Death assays
(Fig. 3A and B). Addition of SH-5, an inhibitor of Akt, blocks IGF-1
induced cell survival both at 4 and 24 h and signiﬁcantly at 24 hFig. 3. IGF-1 increases cell viability and DNA synthesis in retinal capillary endothelial
cells. (A) Treatment of TR-iBRB2 cells with IGF-1 for 24 h increases cell survival
signiﬁcantly (*, pb0.05 versus 0 time, n=4) inMTT assays. (B) IGF-1-induced TR-iBRB2
survival is also measured by Live/Death Fluorescence assays (pb0.05 at both 4 and 24 h
vs. 0 time; n=6). (C) IGF-1 increases DNA content (relative ﬂuorescence units)
signiﬁcantly (*, pb0.05 versus 0 time, n=6) after 24 h but not at 4 h.
Fig. 4. Stable GSK-3β(S9Α) and K-CREB expression prevents IGF-1-induced endothelial
cell survival and ﬁbronectin and cyclin D1 expression. TR-iBRB2 cells were stably
transfected with pcDNA3.1 (control), GSK-3β(S9A) or K-CREB under the pressure of
antibiotic G418. (A) IGF-1 increases TR-iBRB2 cell survival in pcDNA3.1 controls at 24 h as
revealed by MTT assays (*, pb0.05 versus pcDNA3.1 at 0 time, n=6); however, GSK-
3β(S9A) expression blocks IGF-1's ability to induce cell survival at 24 h (grey bar).
Furthermore, K-CREB expression itself reduces cell viability at 0 time and signiﬁcantly
blunts IGF-1 effects at 24 h (~50% reduction at 24 h; #, pb0.001 versus pcDNA 3.1+IGF-1,
n=6, dark bar). (B) Total RNAwas isolated by TRIZOL from stably transfected cellswith or
without IGF-1 treatment andmRNA levels forﬁbronectinwasmeasured by RT-qPCR. They
were normalized to actin. IGF-1 increases ﬁbronectin mRNA expression signiﬁcantly in
pcDNA3.1 cells (~1.7-fold; *, pb0.05 versus control, n=4). However, GSK-3β(S9A)
completely blocks IGF-1-inducedﬁbronectinmRNA expressionwithout a signiﬁcant effect
on basal expression. On the other hand, K-CREB affects both basal and IGF-1-induced
ﬁbronectin expression in TR-iBRB2 cells (#, pb0.05, IGF-1+pcDNA3.1 versus IGF-1+K-
CREB, n=4). (C). Stable GSK-3β(S9A) and K-CREB expression in TR-iBRB2 also blocks
cyclin D1 expression. A representative of n=2 is shown.
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SB216763, an inhibitor of GSK-3β, further increases IGF-1 effects on
TR-iBRB2 survival (Fig. S2, lighter bars). GSK-3β is a negative
regulator of cell growth and viability; therefore, IGF-1 effect is
synergistically enhanced by GSK-3β inhibitor while an inhibition of
Akt leads to blockade of IGF-1-induced cell viability (Fig. S2, darker
bars). IGF-1 also increases DNA content in TR-iBRB2 as measured by
ﬂuorescent CYQUANT binding to deoxynucleic acids (signiﬁcant at
24 h, pb0.05 versus time 0, Fig. 3C). The results indicate that IGF-1 is a
survival and cell cycle progression factor for retinal capillary
endothelial cells in culture.
3.3. GSK-3β and CREB regulate IGF-1 effects on retinal cell viability and
gene expression for ECM and cyclin D1 in endothelial cells
To further understand the contribution of GSK-3β and transcrip-
tion factor CREB in EC survival and gene expression, we employed
cDNA expression vectors for a constitutively active GSK-3β Ser9A and
a dominant negative K-CREB lacking the DNA binding activity. We
established stable TR-iBRB2 cells expressing GSK-3β(S9A) and K-
CREB using G419 pressure. The effect of stable expression of GSK-
3β(S9A) or K-CREBwas ﬁrst established by blockade of a CRE-reporter
activity for secretary alkaline phosphatase (SEAP) in TR-iBRB2 cells as
shown in Fig. S3A. We found that expression of GSK-3β(S9A) or K-
CREB blocks CRE-SEAP activity in these cells suggesting that these
proteins are active and functional intracellularly. IGF-1-induced cell
viability is signiﬁcantly blocked by GSK-3β(S9A) and K-CREB
transfection (Fig. 4A) and K-CREB expressing cells have signiﬁcantly
lower survival rates at 24 h. Our data further show that IGF-1 induces
ﬁbronectin mRNA expression signiﬁcantly in pcDNA3.1 control cells
(Fig. 4B), which is reduced by both GSK-3β(S9A) and K-CREB though
GSK-3β(S9A) is more efﬁcient (Fig. 4B). In addition, we have
previously shown that IGF-1 increases laminin γ1 expression, another
ECMmolecule in renal cells [15,24]. In agreement, IGF-1 also enhances
laminin γ1 protein levels in TR-iBRB2 cells both at 4 and 24 h
(Fig. S3B), and GSK-3β(S9A) and K-CREB completely blocks laminin
γ1 mRNA expression as well (Fig. S3C). Both GSK-3β(S9A) and K-
CREB block IGF-1-induced cyclin D1 expression in TR-iBRB2 cells
when compared to pcDNA3.1 overexpressing cells (Fig. 4C). We did
not observe a change in overall phosphorylation of the endogenous
GSK-3β or CREB in pcNDA3.1 control when compared with GSK-
3β(S9A) or K-CREB overexpressing cells (not shown). Therefore, we
propose that the effects of GSK-3β(S9A) or K-CREB on ECM and cyclin
D1 expression may be due to an interruption of the endogenous GSK-
3β or CREB function.
3.4. IGF-1 down-regulates VE-cadherin and increases endothelial
monolayer permeability
We next examined whether IGF-1 alters the expression of cell
adherens junction molecule VE-cadherin, which is involved in cell–
cell adhesion and membrane permeability. As shown in Fig. 5A, IGF-1
signiﬁcantly reduces VE-cadherin expression (~2.5-fold, pb0.001
versus control, n=4) in TR-iBRB2 cells. However, under these
experimental conditions, we did not observe a signiﬁcant effect of
IGF-1 on ICAM1 expression (Fig. 5A), which is an apical membrane
protein involved in leukocyte adhesion. Our data show that IGF-1
increases TR-iBRB2 monolayer permeability signiﬁcantly as deter-
mined by FITC-dextran leakage in a transwell membrane in culture
(Fig. 5B, pb0.05 versus control). In addition, we also measured the
trans-endothelial/epithelial electrical resistance (TEER) using an
EVOM2 Epithelial Voltohmmeter ﬁtted with a STX2 electrode after
4 days of TR-iBRB2 culture. A reduction in TEER value (~11.6%,
pb0.05) is observed after IGF-1 treatment for 24 h when compared
with the control TEER (Fig. S4), which is in close agreement with the
FITC-dextran leakage observed in Fig. 5B. The effects of GSK-3β in IGF-1-induced VE-cadherin down-regulation and endothelial monolayer
permeability are shown in Fig. 5C andD. Speciﬁcally, stable expression
of GSK-3β(S9A) in TR-iBRB2 cells blunts IGF-1-induced down-
regulation of VE-cadherin and monolayer permeability. ICAM1 and
tubulin levels are not affected by GSK-3β(S9A) expression in TR-
iBRB2 cells.
Involvement of CREB in IGF-1-induced VE-cadherin expression is
also shown in Fig. 5E. Stable K-CREB expression in TR-iBRB2 cell
prevents IGF-1 down-regulation of VE-cadherin while in pcDNA 3.1
control cells IGF-1 still stimulates VE-cadherin suppression. However,
due to the low viability of TR-iBRB2 cells upon K-CREB expression
Fig. 5. IGF-1 down-regulates VE-cadherin expression and increases endothelial monolayer permeability. (A) VE-cadherin expression was detected using pan-cadherin antibodies in
control (no IGF-1) or IGF-1 (100 ng/ml, 24 h) treated pcDNA 3.1 cell extracts. IGF-1 down-regulates VE-cadherin expression signiﬁcantly (~2.7-fold less than the control; *, pb0.001,
n=4). Left panel shows a representative blot and right panel shows the densitometric analysis. IGF-1 has no effect on ICAM1 expression, an apical membrane adhesion molecule
(p=0.2; n=4). (B) IGF-1 increases endothelial monolayer permeability in pcDNA 3.1 transfected TR-iBRB2 cells using semi-permeable transwell cultures (~12.5*, pb0.05 versus
control, n=6) and determined by FITC-dextran leakage as described in Materials and methods. (C) Stable overexpression of the constitutively active GSK-3β(S9A) in TR-iBRB2 cells
impedes IGF-1 down-regulation of VE-cadherin (p=0.2 for control versus IGF-1, n=4). No change in ICAM1 is observed (middle panel). (D) GSK-3β(S9A) overexpression blocks
IGF-1-induced monolayer leakage of FITC-dextran (p=ns, not signiﬁcant between control and IGF-1 treated cells, n=6). (E) In pcDNA 3.1 cells, IGF-1 decreases VE-cadherin
expression (left panel). However, in K-CREB expressing cells, IGF-1 is unable to down-regulate VE-cadherin expression (right panel). ICAM1 and tubulin levels are not affected by
IGF-1 either in pcDNA 3.1 or K-CREB expressing cells. A representative n=3 is shown.
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Together, the data presented here demonstrate that IGF-1 causes VE-
cadherin down-regulation, enhanced ECM expression and cell cycle
progression. These cellular effects may be responsible for the
observed endothelial monolayer permeability and suggest a potential
role for the GSK-3β/CREB axis in vascular dysregulation in DR.
4. Discussion
In this study, we demonstrate for the ﬁrst time, that the GSK-3β/
CREB axis is involved in IGF-1-mediated retinal capillary endothelial
cell survival, ECM/adhesion molecule gene expression, cell cycle
regulation, and endothelial monolayer permeability in in vitro
cultures. Speciﬁcally, (i) IGF-1 enhances phosphorylation of Akt at
Thr308 and its downstream target GSK-3β at Ser9, which increases
TR-iBRB2 viability as measured byMTT and Live/Dead assays; (ii) IGF-1
increases the level of cell cycle progression factor cyclin D1 and DNA
content; (iii) IGF-1 induces ECM expression (ﬁbronectin and laminin
γ1), (iv) down-regulates cell adhesion molecule VE-cadherin expres-
sion and GSK-3β and transcription factor CREB may play a role in this
process; and (v) ﬁnally, IGF-1 induces endothelial monolayer perme-
ability, which is prevented by stable expression of a constitutively active
form of GSK-3β(S9A). Our ﬁndings provide new insights as to howgrowth factors may regulate intracellular signaling pathway(s) in retinal
capillary endothelial cells and alter gene expression for cell–cell and cell–
matrix interaction that lead to endothelial dysfunction and vessel leakage
observed in diabetic ocular diseases. Furthermore, the intracellular Akt/
GSK-3β pathway is also used by different external stimuli including
angiogenic growth factors such as VEGF-A, FGF-2, and BDNF [29–31] and
integrins upon cell–matrix interaction [32] to regulate endothelial
membrane permeability, cell viability, proliferation and angiogenesis
further emphasizing the importance of this pathway in cellular
physiology.
Our results further demonstrate that IGF-1 increases phosphoryla-
tion of cyclic AMP responsive element transcription factor CREB at
Ser133 in retinal endothelial cells and responsible for inducing ECM
genes for ﬁbronectin and laminin γ1 and down-regulation of inter-
cellular adhesion molecule VE-cadherin. Dominant-negative K-CREB
expression in retinal endothelial cells blocks the IGF-1-induced VE-
cadherin down-regulation. Furthermore, IGF-1-induced VE-cadherin
down-regulation and membrane permeability are reversed by stable
expressionof a constitutively activeGSK-3β inwhich Ser9 is replacedby
an alanine. The mechanism by which IGF-1 and/or GSK-3β/CREB axis
causeVE-cadherindegradation isnotunderstood atpresent.However, it
has been demonstrated that matrix metalloproteinase 2 (MMP2) is
responsible for VE-cadherin degradation and retinal blood vessel
Fig. 6. A schematic presentation of IGF-1 signaling, ECM/adhesion molecule expression
and retinal endothelial dysregulation. IGF-1 increases Akt/GSK-3β signaling leading
CREB phosphorylation and altered ECM/adhesion molecule expression and cell cycle
progression (cyclin D1 expression). This potentially leads to retinal endothelial
monolayer hyperpermeability in transwell cultures. These in vitro ﬁndings provide a
potential mechanism for retinal capillary endothelial dysfunction, BRB breakdown and
vessel leakage in diabetic retinopathy.
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1 matrix metalloproteinase (MT1-MMP) expression in a PI3K/Akt-
dependent manner, which in turn activates extracellular MMP2
protease [33]. Furthermore, phosphorylation of CREB at S133 activates
both MT1-MMP and MMP2 expression in various cell types including
human vascular endothelial cells [34]. Our data showing that both GSK-
3β(S9A) and K-CREB block IGF-1-induced VE-cadherin degradation
suggest the participation of MT1-MMP and MMP2 in this process.
(However, GSK-3β and CREB might also directly affect VE-cadherin
expression itself.) Currently, it is unknown howGSK-3β inhibition leads
to enhanced CREB phosphorylation at S133. GSK-3β does not target
CREB S133 directly but phosphorylates at S129, a motif created by
phosphorylated S133 [35]. GSK-3β inhibitors have been suggested as
potential therapies for enhancing insulin-mediated glycogen storage in
insulin-sensitive cells in diabetes [36–38]; however, a role for GSK-3β
and CREB phosphorylation in retinal capillary endothelial (dys)function
and the development of diabetic retinopathy is yet to be determined. In
case of cyclin D1 down-regulation by GSK-3β, it is known that cyclin D1
phosphorylation by GSK-3β leads to its nuclear export and proteosome
degradation [39].
GSK-3β is a negative regulator of growth factor signaling and cell
survival. In general, GSK-3β activity is higher in resting cells and its
phosphorylation at Ser9 is low. Growth factor addition leads to Akt-
dependent phosphorylation of GSK-3β at Ser9 and inactivates its
kinase function [18]. GSK-3β inactivation up-regulates the function of
several downstream target proteins including transcription factor
CREB (as demonstrated in this study), beta-catenin [40], NF-κB [41],
NFAT [42,43], all of which are considered to involve in cell growth,
survival, and proliferation of endothelial cells. We recently showed
that both NF-κB and CREB are involved in ﬁbronectin and pro-
inﬂammatory cytokine interleukin (IL-1β) expression in primary
cultures of Schwann cells and sciatic nerve injury [44]. This may also
explain why stable K-CREB expression alone in TR-iBRB2 does not
reduce the IGF-1-mediated ﬁbronectin expression completely to the
level of the K-CREB control cells without IGF-1 treatment (Fig. 4B).We
have previously shown that CREB is also involved in ECM gene
induction in renal mesangial cells by IGF-1 and under high ambient
glucose condition [23,24,45] and that CREB phosphorylation is
increased in diabetic renal cortex, which correlated positively with
ECM gene expression in the mesangium [15,27]. In this study, we
demonstrate that ﬁbronectin and laminin γ1 expressions are
increased by IGF-1 in retina endothelial cells and that the GSK-3β/
CREB pathway is involved in this process (Fig. 4B and Fig. S3C). In
concert with this observation, we also found that the level of CREB
phosphorylation and ﬁbronectin and laminin γ1 expressions are
elevated in the retina of STZ-induced diabetic rats (Fig. S5). Thus,
excessive ECM accumulation (enhanced expression/decreased degra-
dation) and capillary basement membrane thickening [46] could
potentially disturb endothelial cell–matrix interaction, integrin
signaling and cell-junction function, leading to capillary leakage
[10,12,13] and clinical vasculopathy in DR.
An important aspect of endothelial permeability barrier is the
integrity of the intercellular adhesion molecules between adjacent
cells. Permeability of endothelial junctions is affected by various
vasoactive agents and adhesion of circulating monocytes at apical
cell surface adhesion molecules such as ICAM1, VCAM1, etc., during
inﬂammation [14]. In this study, we observed that IGF-1 down-
regulates VE-cadherin, and induces ECM, and cell cycle progression
factor cyclin D1 expression, but not of ICAM1. On the other hand,
treatment of TR-iBRB2 cells with high glucose (25 mM versus 5 mM
glucose) for 3 days also decreases VE-cadherin and increases ECM
expression (Fig. S6); however, there is no endothelial membrane
leakage under these experimental conditions. Addition of IGF-1 and
high glucose together produced marginal enhancement of IGF-1
effects on endothelial monolayer permeability in transwell cultures
but not signiﬁcant suggesting that various signaling mechanismsoperate to induce endothelial barrier opening in addition to cell
adhesion molecule suppression alone. Busik et al. [47] demonstrated
that hyperglycemia itself is not sufﬁcient to induce oxidative stress
and activation of pro-inﬂammatory and apoptotic pathways in human
retinal endothelial cells but requires glucose-induced cytokine
expression from adjacent cells such as Muller glia. We could consider
here that IGF-1 and growth factors/cytokines induce cell growth and
alter ECM/adhesion molecule expression in endothelial cells under
diabetic conditions, which result in morphology changes and cell
rounding [48,49], leading intercellular junction loosening and
membrane permeability as depicted in Fig. 6. VE-cadherin itself also
plays an important role in the regulation of both adherens junction
and tight junction by upregulating claudin 5 in a PI3K/Akt and FOXO1
dependent pathway [50]. Thus, down-regulation of VE-cadherin by
IGF-1 and GSK-3β/CREB could potentially led to further inhibition of
other adhesion molecules such as claudins. In such a scenario,
maintaining an optimal GSK-3β activity may be advantageous for
upholding the differentiated state of retinal endothelial cells and
maintaining the endothelial cell membrane integrity. We demon-
strate in this study that the expression of an active form of GSK-
3β(S9A) in retinal capillary endothelial cells may be sufﬁcient to
prevent IGF-1-induced ECM and VE-cadherin expression and mono-
layer hyperpermeability. In addition, we cannot rule out that
increased IGF-1 in the vitreous humor in diabetes [3–5] may interact
further with insulin receptor and further amplify its action on Akt/
GSK-3β and CREB phosphorylation. Retina EC cells express both IGF-1
and insulin receptors and high glucose may increase insulin receptor
expression (Fig. S7). Further studies will delineate the putative role of
IGF-1 and insulin receptors in retinal endothelial cells under high
ambient glucose and the signaling mechanisms.
In conclusion, our results provide a potential role of the GSK-3β/
CREB axis in IGF-1/growth factor-mediated aberrant ECM/adhesion
molecule expression, cell cycle regulation and endothelial monolayer
hyperpermeability. Alterations in ECM and adhesion molecule
expression in retinal endothelial cells and blood vessel leakage in
diabetes have been well studied [11,51,52]. However, further
investigation is necessary to establish a potential role of the GSK-
3β/CREB/cyclin D1 and altered ECM expression and vessel thickening
1087T.S. Devi et al. / Biochimica et Biophysica Acta 1812 (2011) 1080–1088in microvascular dysfunction and blood–retinal barrier breakdown in
models of diabetic retinopathy as well as diabetic patients.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbadis.2011.04.007.
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